Dasatinib attenuates pressure overload induced cardiac fibrosis in a murine transverse aortic constriction model

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Balasubramanian, Sundaravadivel ^a   Pleasant, Dorea L ^a   Kasiganesan, Harinath ^a   Quinones, Lakeya ^a   Zhang, Yuhua ^a   Sundararaj, Kamala P ^a   Roche, Sandra ^b   O'Connor, Robert ^b   Bradshaw, Amy D ^a   Kuppuswamy, Dhandapani ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DASATINIB; FIBRONECTIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; HISTONE H2B; INSULIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; S PHASE KINASE ASSOCIATED PROTEIN 2; SCLEROPROTEIN; BIOLOGICAL MARKER; FOCAL ADHESION KINASE 1; PTK2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HEART FIBROBLAST; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; MURINE MODEL; NONHUMAN; OSMOTIC PUMP; PRESSURE; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; CARDIAC MUSCLE; CELL MOTION; CELL NUCLEUS; DOSE RESPONSE; DRUG EFFECTS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FIBROSIS; HEART; LIGATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; AORTA; BIOMARKERS; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CONSTRICTION; DASATINIB; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; HEART; MALE; MICE; MYOCARDIUM; PRESSURE; VENTRICULAR FUNCTION, LEFT;

EID: 84948783394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140273     Document Type: Article

References (48)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensinaldosterone system. Circulation. 1991; 83(6): 1849-65. Epub 1991/06/01. PMID: 1828192.
2. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovascular research. 2000; 45 (4): 813-25. Epub 2000/03/23. PMID: 10728407.
3. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis. Hypertension research: Official journal of the Japanese Society of Hypertension. 2005; 28(6): 483-90. Epub 2005/10/20. doi: 10.1291/hypres.28.483 PMID: 16231753.
4. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: Application to heart failure with a preserved ejection fraction. Journal of cardiovascular translational research. 2013; 6(4): 501-15. Epub 2013/05/30. doi: 10.1007/s12265-013-9472-1 PMID: 23716130.
5. Zile MR, Baicu CF, Ikonomidis J, Stroud RE, Nietert PJ, Bradshaw AD, et al. Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin. Circulation. 2015. Epub 2015/02/01. doi: 10.1161/CIRCULATIONAHA.114.013215 PMID: 25637629.
6. Wang X, McLennan SV, Allen TJ, Twigg SM. Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes. Journal of cell communication and signaling. 2010; 4(1): 15-23. Epub 2010/03/03. doi: 10.1007/s12079-009-0083-1 PMID: 20195389; PubMed Central PMCID: PMC2821474.
7. Touvron M, Escoubet B, Mericskay M, Angelini A, Lamotte L, Santini MP, et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Disease models & mechanisms. 2012; 5(4): 481-91. Epub 2012/05/09. doi: 10.1242/dmm.009456 PMID: 22563064; PubMed Central PMCID: PMC3380711.
8. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute. 2010; 102(1): 14-25. Epub 2009/12/17. doi: 10.1093/jnci/djp440 PMID: 20007921; PubMed Central PMCID: PMC2802286.
9. Balasubramanian S, Quinones L, Kasiganesan H, Zhang Y, Pleasant DL, Sundararaj KP, et al. beta3 integrin in cardiac fibroblast is critical for extracellular matrix accumulation during pressure overload hypertrophy in mouse. PLoS One. 2012; 7(9): E45076. Epub 2012/09/18. doi: 10.1371/journal.pone. 0045076 PMID: 22984613; PubMed Central PMCID: PMC3440340.
10. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P, et al. Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. Arthritis and rheumatism. 2008; 58 (5): 1475-84. Epub 2008/04/29. doi: 10.1002/art.23436 PMID: 18438865.
11. Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. Biochimica et biophysica acta. 2013; 1832(7): 897-904. Epub 2012/06/26. doi: 10. 1016/j.bbadis.2012.06.008 PMID: 22728287.
12. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB journal: Official publication of the Federation of American Societies for Experimental Biology. 2008; 22(7): 2214-22. Epub 2008/03/11. doi: 10.1096/fj.07-105627 PMID: 18326784.
13. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95(5): 2509-14. PMID: 9482916.
14. Willey CD, Balasubramanian S, Rodriguez Rosas MC, Ross RS, Kuppuswamy D. Focal complex formation in adult cardiomyocytes is accompanied by the activation of beta3 integrin and c-Src. J Mol Cell Cardiol. 2003; 35(6): 671-83. Epub 2003/06/06. S0022282803001123 [pii]. PMID: 12788385.
15. Palanisamy AP, Suryakumar G, Panneerselvam K, Willey CD, Kuppuswamy D. A Kinase-Independent Function of c-Src Mediates p130Cas Phosphorylation at the Serine-639 Site in Pressure Overloaded Myocardium. J Cell Biochem. 2015. Epub 2015/05/16. doi: 10.1002/jcb.25224 PMID: 25976166.
16. Johnston RK, Balasubramanian S, Kasiganesan H, Baicu CF, Zile MR, Kuppuswamy D. Beta3 integrin- mediated ubiquitination activates survival signaling during myocardial hypertrophy. FASEB J. 2009; 23(8): 2759-71. Epub 2009/04/15. fj.08-127480 [pii] doi: 10.1096/fj.08-127480 PMID: 19364763; PubMed Central PMCID: PMC2717769.
17. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, et al. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in Two-dimensional Echocardiography. Circulation. 1980; 62(2): 212-7. Epub 1980/08/01. PMID: 7397962.
18. Suryakumar G, Kasiganesan H, Balasubramanian S, Kuppuswamy D. Lack of beta3 integrin signaling contributes to calpain-mediated myocardial cell loss in pressure-overloaded myocardium. Journal of cardiovascular pharmacology. 2010; 55(6): 567-73. Epub 2010/03/13. doi: 10.1097/FJC. 0b013e3181d9f5d4 PMID: 20224428; PubMed Central PMCID: PMC3319054.
19. Harris BS, Zhang Y, Card L, Rivera LB, Brekken RA, Bradshaw AD. SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. American journal of physiology Heart and circulatory physiology. 2011; 301(3): H841-7. Epub 2011/06/15. doi: 10.1152/ajpheart.01247.2010 PMID: 21666116; PubMed Central PMCID: PMC3191098.
20. Kent RL, Mann DL, Urabe Y, Hisano R, Hewett KW, Loughnane M, et al. Contractile function of isolated feline cardiocytes in response to viscous loading. Am J Physiol. 1989; 257(5 Pt 2): H1717-27. Epub 1989/11/11. PMID: 2589523.
21. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Boggs J, Lacy JM, et al. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: Role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation. 2009; 119(2): 269-80. PMID: 19118257. doi: 10.1161/CIRCULATIONAHA.108.773424
22. Balasubramanian S, Johnston RK, Moschella PC, Mani SK, Tuxworth WJ Jr., Kuppuswamy D. mTOR in growth and protection of hypertrophying myocardium. Cardiovasc Hematol Agents Med Chem. 2009; 7(1): 52-63. PMID: 19149544.
23. Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Molecular biology of the cell. 1999; 10(5): 1569-79. Epub 1999/05/08. PMID: 10233163; PubMed Central PMCID: PMC25344.
24. Roche S, McMahon G, Clynes M, O'Connor R. Development of a high-performance liquid chromatographic- mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2009; 877(31): 3982-90. Epub 2009/10/27. PMID: 19854117.
25. Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford). 2008; 47 Suppl 5: V10-1. Epub 2008/09/17. PMID: 18784126.
26. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014; 349(2): 209-20. Epub 2014/02/22. doi: 10.1124/jpet.113.208223 PMID: 24556663.
27. Snyder DS. New approved dasatinib regimen available for clinical use. Expert review of anticancer therapy. 2009; 9(3): 285-92. Epub 2009/03/12. doi: 10.1586/14737140.9.3.285 PMID: 19275507.
28. Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008; 118(1): 84-95. Epub 2008/07/02. doi: 10.1161/ CIRCULATIONAHA.108.776831 PMID: 18591451; PubMed Central PMCID: PMC2735334.
29. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB journal: Official publication of the Federation of American Societies for Experimental Biology. 2008; 22 (3): 659-61. Epub 2007/10/19. doi: 10.1096/fj.07-9574LSF PMID: 17942826.
30. Kuppuswamy D, Kerr C, Narishige T, Kasi VS, Menick DR, Cooper G. Association of tyrosine-phosphorylated c-Src with the cytoskeleton of hypertrophying myocardium. J Biol Chem. 1997; 272 (7): 4500-8. PMID: 9020175.
31. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis & tissue repair. 2012; 5(Suppl 1 Proceedings of Fibroproliferative disorders: From biochemical analysis to targeted therapiesPetro E Petrides and David Brenner): S17. Epub 2012/ 12/25. doi: 10.1186/1755-1536-5-S1-S17 PMID: 23259769; PubMed Central PMCID: PMC3368775.
32. Lau AT, Lee SY, Xu YM, Zheng D, Cho YY, Zhu F, et al. Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem. 2011; 286(30): 26628-37. Epub 2011/06/08. doi: 10.1074/ jbc.M110.215590 PMID: 21646345; PubMed Central PMCID: PMC3143627.
33. Mani SK, Shiraishi H, Balasubramanian S, Yamane K, Chellaiah M, Cooper G, et al. In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium. Am J Physiol Heart Circ Physiol. 2008; 295(1): H314-26. PMID: 18487434. doi: 10.1152/ ajpheart.00085.2008
34. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a populationbased cohort. Journal of the American College of Cardiology. 1999; 33(7): 1948-55. Epub 1999/06/11. PMID: 10362198.
35. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr., Cruickshank JM, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992; 20(1): 3-16. PMID: 1318886.
36. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005; 45: 657-87. PMID: 15822192.
37. Ren J, Avery J, Zhao H, Schneider JG, Ross FP, Muslin AJ. Beta3 integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol. 2007; 42(2): 367-77. PMID: 17184791.
38. Clemente CF, Tornatore TF, Theizen TH, Deckmann AC, Pereira TC, Lopes-Cendes I, et al. Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice. Circ Res. 2007; 101(12): 1339-48. PMID: 17947798.
39. Lucas JA, Zhang Y, Li P, Gong K, Miller AP, Hassan E, et al. Inhibition of transforming growth factorbeta signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. American journal of physiology Heart and circulatory physiology. 2010; 298(2): H424-32. Epub 2009/11/26. doi: 10.1152/ajpheart.00529.2009 PMID: 19933419; PubMed Central PMCID: PMC2822586.
40. Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: Role of the renin-angiotensin-aldosterone system. The Medical clinics of North America. 2004; 88(1): 83-97. Epub 2004/02/12. PMID: 14871052.
41. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010; 106(11): 1675-80. Epub 2010/06/12. 106/ 11/1675 [pii] doi: 10.1161/CIRCRESAHA.110.217737 PMID: 20538689.
42. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 106(11): 1675-80. PMID: 20538689. doi: 10. 1161/CIRCRESAHA.110.217737
43. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, et al. The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009. PMID: 19494352.
44. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood. 2014; 123(15): 2317-24. Epub 2014/02/27. doi: 10.1182/blood-2013-10-532341 PMID: 24569263.
45. Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, et al. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett. 2012; 3(4): 807-15. Epub 2012/06/29. doi: 10.3892/ol.2012.579 PMID: 22740998; PubMed Central PMCID: PMC3362483.
46. Sonomura K, Okigaki M, Kimura T, Matsuoka E, Shiotsu Y, Adachi T, et al. The kinase Pyk2 is involved in renal fibrosis by means of mechanical stretch-induced growth factor expression in renal tubules. Kidney international. 2012; 81(5): 449-57. Epub 2011/12/14. doi: 10.1038/ki.2011.403 PMID: 22157654.
47. Abi-Gerges N, Pointon A, Pullen GF, Morton MJ, Oldman KL, Armstrong D, et al. Preservation of cardiomyocytes from the adult heart. Journal of molecular and cellular cardiology. 2013; 64: 108-19. Epub 2013/09/21. doi: 10.1016/j.yjmcc.2013.09.004 PMID: 24051370.
48. Ekwall B, Silano V, Paganuzzi-Stammati A, Zucco F. Toxicity tests with mammalian cell cultures. Short-term Toxicity tests for non-genotoxic effects, Edited by Bourdeau et al; Published by John Wiley and Sons Ltd. 1990: 76-97. Epub 1990/01/01.